Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S055 - Chronic Pruritus: Bedside to Bench Perspectives

Monday, February 19; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Evaluate the patient who has chronic itch.
  • Formulate a treatment plan for the patient who suffers from chronic itch.

Description

Chronic pruritus has considerable impact on patient quality of life. Successful treatment has been a challenge that is beginning to be met as a result of advances in understanding of physiology and pathophysiology accompanied by targeted therapeutic approaches. This session is geared toward the practicing physician. It addresses advances in our understanding of itch, workup of the itchy patient and cutting edge approaches to treatment. This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.

Disclosures

  • Elmariah, Sarina, MD: no financial relationships exist with commercial interests.
  • Kim, Brian S, MD: Celgene Corporation – A(H); Incyte Corporation – C(Fees); Regeneron – C(H);
  • Lerner, Ethan A., MD, PhD: Celgene – A(Fees); Dermira – A(Fees); Lerner Medical Devices, Inc. – F(NC); Menlo Therapeutics – A(Fees); Sienna Biopharmaceuticals – A(Fees); Toray Industries, Inc. – C(Fees);
  • Stander, Sonja, MD: Tigercat Pharma, Inc. – A(H); Trevi Therapeutics – C(H);
  • Szepietowski, Jacek C, MD: AbbVie – A(H), I(H), SP(H); Almirall – A(H), SP(H); Celgene Corporation – A(H); Janssen-Cilag – I(H); Leo Pharma Inc. – A(H); Novartis – A(H), I(H), SP(H); Pierre Fabre Dermatologie – A(H); Regeneron – I(H); Sandoz, a Novartis company – Data Safety Monitoring Board(H); Sanofi – SP(H); Sienna Biopharmaceuticals – A(H); Trevi Therapeutics – A(H); UCB – SP(H);
  • Yosipovitch, Gil, MD: Galderma Laboratories, L.P. – A(H); Kiniksa Pharmaceuticals, Ltd. – I(Grants/Research Funding); Menlo Therapeutics – A(H), I(Grants/Research Funding); Novartis – C(H); OPKO Health, Inc – C(H); Pfizer Inc. – A(H), I(Grants/Research Funding); Sanofi/Regeneron – A(H); Sienna Biopharmaceuticals – A(H); Sun Pharmaceutical Industries Ltd. – I(Grants/Research Funding); Trevi Therapeutics – A(H);
Schedule
Monday, February 19
1:00 PM
Dr. Tey / The cutaneous nervous system in pruritic dermatoses: a 3-dimensional perspective
1:30 PM
Dr. Stander / New therapies for pruritus
2:00 PM
Dr. Elmariah / Workup of the itchy patient
2:30 PM
Dr. Szepietowski / Systemic pruritus
3:00 PM
Dr. Kim / Itchy conversations between the neuro and immune systems
3:25 PM
Dr. Yosipovitch / Interesting itches
Event Details
  • Date
    Monday, February 19
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 30B
  • CME Credits
    3.00
  • Type
    MOC
Directors/Co-Directors
  • Ethan A. Lerner, MD, PhD, FAAD
Speakers
  • Brian S Kim, MD, FAAD - Handout
  • Gil Yosipovitch, MD
  • Hong Liang Tey, MBBS
  • Jacek C Szepietowski, MD
  • Sarina Elmariah, MD, FAAD
  • Sonja Stander, MD - Handout